Northern Trust Corp Purchases 22,266 Shares of Harrow, Inc. (NASDAQ:HROW)

Northern Trust Corp boosted its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 319,084 shares of the company's stock after acquiring an additional 22,266 shares during the period. Northern Trust Corp owned approximately 0.90% of Harrow worth $10,705,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares during the period. Aquatic Capital Management LLC bought a new position in Harrow in the fourth quarter valued at approximately $78,000. AlphaQuest LLC lifted its stake in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after buying an additional 2,889 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Harrow in the fourth quarter valued at approximately $214,000. Finally, Maridea Wealth Management LLC bought a new stake in shares of Harrow during the fourth quarter worth $222,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Stock Down 4.8%

Shares of HROW stock traded down $1.34 during trading on Wednesday, reaching $26.73. The company's stock had a trading volume of 301,365 shares, compared to its average volume of 496,237. Harrow, Inc. has a one year low of $15.97 and a one year high of $59.23. The business has a fifty day moving average price of $25.26 and a 200-day moving average price of $31.67. The company has a market cap of $980.59 million, a price-to-earnings ratio of -28.44 and a beta of 0.41. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HROW shares. B. Riley cut their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. HC Wainwright boosted their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.